Reactions Weekly

, Volume 1730, Issue 1, pp 24–24 | Cite as

Alglucosidase α

Formation of drug specific neutralising antibodies, infusion associated reactions and lack of edfficacy: 4 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case series of four infants [ages at events onsets not clearly stated], one male and three female infants were described, who developed neutralising antibodies to alglucosidase-α during treatment with recombinant alglucosidase-α for infantile-onset Pompe disease (IPD). Additionally, three of the four patients developed infusion associated reactions (IAR), which manifested as vomiting, fever and tachycardia in one infant and hypotension, tongue and lip swelling, reduced oxygen saturations, tachycardia, fever and rash in one infant during treatment with recombinant alglucosidase-α. Two patients died secondary to alglucosidase-α efficacy attenuation due to high sustained titres of neutralising antibodies (HSAT) [not all durations of treatments to reactions onsets and outcomes...


  1. Owens P, et al. Infantile-onset Pompe disease: A case series highlighting early clinical features, spectrum of disease severity and treatment response. Journal of Paediatrics and Child Health 54: 1255-1261, No. 11, Nov 2018. Available from: URL: - Australia

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations